Fig. 2

Baseline plasma levels of CD20+ EVs are significantly elevated in AMC-034 trial participants with DLBCL tumor subtype and IPI scores of 2 to 3. The box plot shows the distribution of CD20 concentration (ng/ml) on EVs according to IPI scores 0 to 1 (N = 18) and 2 to 3 (N = 29) for DLBCL tumor subtype. A two-sided Wilcoxon two-sample test was conducted, where p = 0.050.